menu
    • menu

    Company profile for Ensem Therapeutics

    NEW Drugs in Dev: 3
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ENSEM Therapeutics (“ENSEM”) is a Boston-based, preclinical stage biopharmaceutical company focused on high value and difficult-to-drug targets in oncology to address unmet medical needs. The name ENSEM symbolizes innovations via the integration of groundbreaking technologies to decipher structural ENSEMbles and kinetics for drug design. The company’s mission is to discover, develop, and commercialize transformative onco...
    ENSEM Therapeutics (“ENSEM”) is a Boston-based, preclinical stage biopharmaceutical company focused on high value and difficult-to-drug targets in oncology to address unmet medical needs. The name ENSEM symbolizes innovations via the integration of groundbreaking technologies to decipher structural ENSEMbles and kinetics for drug design. The company’s mission is to discover, develop, and commercialize transformative oncology therapies for patients, while leading the advancement of AI-driven structural ensemble and computational drug design.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ensem TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Boston Ave, Suite 1875 Medford MA 02155
    Telephone
    Telephone
    781-874-2500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.ensemtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ensemtx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ensem Therapeutics Initiates First Patient Dosing In China
    Ensem Therapeutics Initiates First Patient Dosing In China

    02 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260202247387/en/Ensem-Therapeutics-Doses-First-Patient-in-China-in-ETX-636-Global-Phase-12-Study

    BUSINESSWIRE
    02 Feb 2026
    Share Share
    Ensem Announces ETX-636 Granted Fast Track Designation by FDA
    Ensem Announces ETX-636 Granted Fast Track Designation by FDA

    01 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251001083267/en/Ensem-Therapeutics-Announces-ETX-636-Granted-Fast-Track-Designation-by-the-FDA-for-Advanced-Breast-Cancer

    BUSINESSWIRE
    01 Oct 2025
    Share Share
    Ensem Therapeutics Doses First Patient in ETX-636 Trial
    Ensem Therapeutics Doses First Patient in ETX-636 Trial

    01 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250701035370/en/Ensem-Therapeutics-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-of-ETX-636-a-Potential-Best-In-Class-Allosteric-Pan-Mutant-Selective-PI3K-Inhibitor-and-Degrader

    BUSINESSWIRE
    01 Jul 2025
    Share Share
    Ensem Therapeutics gets FDA clearance for ETX-636 clinical trials
    Ensem Therapeutics gets FDA clearance for ETX-636 clinical trials

    22 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250422440145/en/Ensem-Therapeutics-Announces-U.S.-FDA-IND-Clearance-to-Initiate-Clinical-Development-of-ETX-636

    BUSINESSWIRE
    22 Apr 2025
    Share Share
    Ensem Announces Presentation at 43rd Annual J.P. Morgan Conference
    Ensem Announces Presentation at 43rd Annual J.P. Morgan Conference

    06 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250106220360/en

    BUSINESSWIRE
    06 Jan 2025
    Share Share
    Ensem to Present Preclinical Data on CDK2 Inhibitor at SABCS
    Ensem to Present Preclinical Data on CDK2 Inhibitor at SABCS

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210178696/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search